Published: June 1, 2024
Citation: Antimicrobial resistance: an agenda for all. The Lancet, The Lancet, Volume 403, Issue 10442, 2349
Summary: This new Lancet Series on AMR provides key evidence on interventions and investments to inform decision making to achieve sustainable access to effective antibiotics and accelerate progress in addressing AMR, as well as proposing achievable global targets in humans and animals for 2030. The Series argues that the overarching problem is the high overall burden of bacterial infection, and that AMR is a symptom of global health inequities that are not addressable by an agenda focused on high-income countries.
The Series emphasises the human costs of AMR. AMR is no longer an abstract consideration that threatens to arise in the future—it already has a huge impact on health. A 2022
study estimated that almost 5 million deaths per year are associated with drug-resistant bacteria, with a higher burden among low-income and middle-income countries (LMICs). This Series further emphasises the effects of bacterial AMR across the life course: newborns, older people, and people with chronic illnesses are particularly susceptible. These effects compromise the achievement of the Sustainable Development Goals related to healthy lives and wellbeing at all ages, newborn mortality, poverty alleviation, and economic growth. Treating resistant bacterial infections is estimated to
cost US$412 billion annually, and productivity losses due to AMR could account for $443 billion per year. These issues cannot afford to wait any longer.
For a full list of articles, click
here.
-
Resource Attachments:
-
https://globalhandwashing.org/wp-content/uploads/2024/11/AMR-Lancet-Series.pdf
(pdf)
TAGS:
Briefing PaperPresentationAdvocacy MaterialsPartnership DocumentsResearch Advocacy & PolicyHygiene in Health FacilitiesRx Hand Hygiene